Moy, Beverly <br/><br/>
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.  [electronic resource] 

 -  The oncologist  Apr 2014 
 - 348-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2014-0021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aniline Compounds--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Aromatase Inhibitors--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Letrozole<br/>Nitriles--adverse effects<br/>Postmenopause<br/>Protein Kinase Inhibitors--adverse effects<br/>Quinolines--adverse effects<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Triazoles--adverse effects